Latest Breaking News On - University of california law san francisco - Page 14 : comparemela.com

Sheldon Cooper/SOPA Images/LightRocket via Getty Images(NEW YORK)  In a move welcomed by advocates, a treatment for multi-drug resistant tuberculosis could soon become more accessible for millions of people worldwide. Although tuberculosis is uncommon in the U.S., it is the top infectious disease killer worldwide after COVID-19, claiming an estimated 1.6 million lives in 2021, according to the World Health Organization. A life-saving drug called bedaquiline, when used along with other medications, works to kill the bacteria that causes multi-drug resistant tuberculosis (MDR-TB). While the drug’s primary patent was set to expire this week, allowing less-expensive generic versions to be manufactured and distributed, Johnson & Johnson, which makes and markets bedaquiline under the brand name Sirturo, had planned to utilize a secondary patent to extend their control of it until the end of 2027, advocates say. In a now-viral YouTube video, author and advocate John Green protested Joh

United statesSierra leoneJohn greenRobin feldmanJohn brownsteinCarole mitnickHarvard medical schoolTb partnership global drug facilityDoctors without bordersCenters for diseaseUniversity of california law san franciscoWorld health organizationHarvard medical school carole mitnickTb partnershipDrug administrationPartners in health